Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,653 across all filing types
Latest filing 2024-04-24 Investor Presentation
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于举行2023年度网上业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the holding of the 2023 annual performance explanation meeting (业绩说明会) by 贝达药业股份有限公司. It mentions that the full 2023 annual report has already been disclosed on April 20, 2024, and this announcement is to inform investors about the upcoming online performance explanation meeting scheduled for May 7, 2024. The document is short (749 characters) and serves as a notice for an investor presentation event rather than the report itself. Therefore, it fits the category of Investor Presentation (IP) as it focuses on financial results explanation and investor communication.
2024-04-24 Chinese
关于BPI-16350取得Ⅲ期临床试验总结报告的提示性公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (1374 characters) from Betta Pharmaceuticals regarding the acquisition of a Phase III clinical trial summary report for their drug BPI-16350. It provides details about the drug, trial results, and regulatory context but does not contain full financial statements or detailed financial analysis. It is an informative disclosure about clinical trial progress and regulatory steps, not a full report like an Annual Report or Interim Report. The document also does not fit categories like earnings release or management report. Given its length and content, it is best classified as a Regulatory Filing (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2024-04-24 Chinese
2023年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the company's fundraising activities, specifically focusing on the storage and usage of funds raised through stock issuance in 2023. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, includes detailed tables of funds raised, usage, balances, and changes in investment projects. The document is titled as a "专项报告" (special report) on the storage and use of raised funds for the year 2023. It contains substantive financial data and analysis related to capital raised and its deployment, including changes in project funding and compliance with regulatory requirements. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. It is not an announcement of a report, nor a full annual or interim report, but a specialized report on fundraising and capital usage.
2024-04-19 Chinese
2023年度募集资金年度存放与使用情况鉴证报告
Audit Report / Information Classification · 95% confidence The document is a detailed report titled '2023年度募集资金存放与使用情况专项报告的鉴证报告' which translates to '2023 Annual Fundraising Funds Deposit and Usage Special Report Assurance Report' for 贝达药业股份有限公司 (Betta Pharmaceuticals Co., Ltd.). It includes extensive financial data on the company's fundraising activities, usage of raised funds, compliance with regulatory requirements, and auditor's assurance on the report. The document references Chinese regulatory guidelines on fundraising management and includes auditor's verification and conclusions. It is not a general annual report or earnings release but a specialized audit/assurance report on the use of raised funds. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit/assurance report on a specific financial aspect (fundraising funds usage) and not a full annual report or other category. The document length is substantial and contains detailed financial data and auditor's opinion, confirming it is the report itself, not just an announcement or certification letter. Therefore, the appropriate classification is AR with high confidence.
2024-04-19 Chinese
关于续聘2024年度会计师事务所的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of the accounting firm (auditor) for the fiscal year 2024. It details the auditor's qualifications, past performance, and the board and audit committee's approval of the reappointment proposal. It explicitly states that the reappointment is subject to approval at the 2023 annual shareholders meeting. The document does not contain any financial statements or audit reports themselves but is an announcement about the auditor appointment process and related governance matters. The document length is under 5,000 characters and is primarily an announcement rather than a full audit report or annual report. Therefore, it fits best under the category of Audit Report / Information (AR) because it relates to audit firm appointment and audit-related disclosures, but it is not a full annual report or audit report itself. It is not a Report Publication Announcement (RPA) because it is not announcing the publication of a report but the auditor reappointment. Hence, the classification is AR with high confidence.
2024-04-19 Chinese
2023年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled "审计报告及财务报表 二○二三年度" which translates to "Audit Report and Financial Statements for the Year 2023." It includes detailed audit opinions, key audit matters, and extensive financial statements such as consolidated and parent company balance sheets, profit and loss statements, and cash flow statements for the fiscal year ending December 31, 2023. The presence of an audit opinion section and detailed financial data confirms this is a full audit report with financial statements, not just an announcement or certification. The document length is substantial (15,000 characters), containing comprehensive financial data and audit details. Therefore, the document fits the category of Audit Report / Information (AR).
2024-04-19 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.